[go: up one dir, main page]

WO2005066188A1 - A process for the preparation of 2-(imidazol-1-yl)-1-hydroxyethane-1, 1-diphosphonic acid - Google Patents

A process for the preparation of 2-(imidazol-1-yl)-1-hydroxyethane-1, 1-diphosphonic acid Download PDF

Info

Publication number
WO2005066188A1
WO2005066188A1 PCT/IN2004/000320 IN2004000320W WO2005066188A1 WO 2005066188 A1 WO2005066188 A1 WO 2005066188A1 IN 2004000320 W IN2004000320 W IN 2004000320W WO 2005066188 A1 WO2005066188 A1 WO 2005066188A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
imidazol
fomiula
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2004/000320
Other languages
French (fr)
Inventor
Vijaykumar Muljibhai Patel
Trinadha Rao Chitturi
Rajamannar Thennati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of WO2005066188A1 publication Critical patent/WO2005066188A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • the present invention relates to a process for the preparation of 2 ⁇ (imidazol-l-yl)-l- hydroxyethane- 1 , 1 -diphosphonic acid, compound of formula 1, commonly known as zoledronic acid (INN Name) used as medicament for treatment of diseases associated with impairment of calcium metabolism.
  • United States Patent No. 4,939,130 (Assigned to: Ciba-Geigy Corporation) discloses the preparation of zoledronic acid, compound of formula 1, from imidazol-1-ylacetic acid, compound of formula 2, o Formula 2 by two methods viz.
  • the preparation of the ester involves treating imidazole with the required haloacetates in presence of potassium hydroxide and potassium carbonate in methylene dichloride and facilitator like l,5-bis[(N-benzyl-N,N-diethylammonio)ethyl]ether dichloride (BBDED).
  • BBDED methylene dichloride and facilitator like l,5-bis[(N-benzyl-N,N-diethylammonio)ethyl]ether dichloride
  • Method (a) prepares benzyl esters of imidazol-1 -yl acetic acid in low yield.
  • Method (b) discloses preparation of methyl and malonyl esters of imidazol-1 - ylacetic acid in 70-80% and 49% yield respectively. Hydrolysis of these compounds will further reduce the overall yield of imidazol-1 -ylacetic acid, compound of fomiula 2.
  • the process of the present invention prepares the benzyl ester of imidazol-1 -ylacetic acid, compound of fomiula 3, in greater than 80% yield. All the above mentioned prior art references prepare the haloacetate or trimethylsilyl haloacetate separately and then treat it with imidazole.
  • the process of the present invention prepares the compound of formula 3, by directly reacting imidazole with benzyl alcohol and chloroacetyl chloride in one pot. It does not need a separate unit operation for preparation of the haloacetatae.
  • the benzyl ester of imidazol-1 -ylacetic acid, compound of formula 3 may be prepared in high yields, in one pot in a homogenous system by a novel method without the use of expensive haloacetates.
  • the benzyl 1-imidazolylacetate, compound of fomiula 3 is then converted to imidazol-1 -ylacetic acid, compound of fomiula 2, by catalytic hydrogenolysis or by acid hydrolysis which is further converted to compound of fomiula 1.
  • the object of the present invention is to provide a simple and cost-effective process for the preparation of compound of fomiula 1.
  • Another object of the present invention is to prepare compound of fomiula 3 by a novel process in high yields by simple, convenient and commercially viable method from readily available and cheap reagents.
  • the compound of fomiula 3 can be used as an intermediate for the preparation of imidazole derivatives such as compound of fomiula 1.
  • the present invention provides a process for preparation of 2-(imidazol-l-yl)- 1- hydroxyethane- 1,1 -diphosphonic acid, compound of formula 1, said process comprising Formula 1
  • Formula 2 (c) converting compound of fomiula 2 to compound of fomiula 1.
  • the present invention also provides a process for preparing benzyl 1-imidazolylacetate, compound of formula 3, said process comprising
  • the compound of fo ⁇ nula 3, benzyl 1-imidazolylacetate is prepared by reaction of imidazole with chloroacetyl chloride and benzyl alcohol in an organic solvent.
  • the process of the present invention prepares compound of fomiula 3, benzyl- 1- imidazolyl acetate, in one pot starting from chloroacetyl chloride, benzyl alcohol and imidazole.
  • Imidazole is present in molar excess over chloroacetyl chloride and acts as reactant as well as base.
  • the molar ratio of chloroacetyl chloride: imidazole may be selected in the range from 1 :2 to about 1 :6, preferably 1 :3.
  • the process of the present invention is carried out in absence of additional base.
  • additional inorganic base such as hydroxides, carbonates of alkali and alkaline earth metal salts such as potassium hydroxide &/or potassium carbonate and the like, or an organic base like tertiary alkylamines, such as triethylamine, diisopropylethylamine etc.
  • the reaction mixture of the present invention is homogenous, as imidazole is soluble in organic solvent, and a separate additional base is not used in the reaction. Accordingly the process of the present invention obviates the requirement of a facilitator such as a phase transfer catalyst.
  • the organic solvent may be selected from non-polar solvents like linear or cyclic aliphatic or aromatic hydrocarbons such as n-hexane, n-heptane, cyclohexane, methylcyclohexane, toluene, ethylbenzene, xylene and the like; aliphatic or aromatic halogenated hydrocarbons such as methylene dichloride, ethylene dichloride, tetrachloroethane, trichloroethane, chlorobenzene, dichlorobenzene and the like; ethereal solvents, such as diethylether, di-isopropylether, dioxane, tetrahydrofuran and the like; esters such as ethyl acetate, tert-butyl acetate and the like; or inert polar aprotic solvents such as acetonitrile, sulfolane and the like.
  • the reaction may be carried out at temperature ranging from 30 to 100°C, preferably 40 to 70°C.
  • the compound of formula 3 is thus prepared in high yields by simple, convenient and commercially viable method from readily available, and cheap reagents with reduced number of unit operations.
  • the compound of fomiula 2, imidazol-1 -ylacetic acid is obtained by debenzylating benzyl 1- imidazolyl acetate, compound of formula 3.
  • the debenzylation may be carried by catalytic hydrogenolysis or by acidic hydrolysis.
  • the debenzylation by catalytic hydrogenolysis may be performed in presence of metal catalysts like palladium, platinum, ruthenium or rhodium and the like.
  • the catalytic hydrogenolysis may be carried out in a solvent at atmospheric pressure or at higher pressures, at temperature between 5 and 100°C.
  • the solvent maybe selected from a polar protic solvent such as methanol, ethanol, isopropanol, acetic acid and the like; or in aromatic hydrocarbons such as toluene, or esters such as ethyl acetate, tert-butyl acetate and the like
  • debenzylation may be perfo ⁇ ned by acidic hydrolysis with a mineral or organic acid, wherein mineral acid may be selected from hydrochloric, sulfuric, hydrobromic and the like; and the organic acid may be selected from acetic, oxalic, para- toluenesulfonic, methaesulfonic and the like.
  • Acidic hydrolysis may be earned out by at temperature of about 20 -100 °C for 2-6 hours preferably at about 40 to 70°C.
  • the compound of fomiula 2, imidazol-1 -ylacetic acid is then converted to 2-(imidazol-l- yl)-l-hydroxyethane- 1,1 -diphosphonic acid, compound of fomiula 1 using standard methods known to those skilled in the art such as United States Patent No. 4,939,130.
  • a process disclosed in our copending Indian Patent Application No. 837/MUM/2003 may be used.
  • Example 1 Synthesis of benzyl 1-imidazolyl acetate (compound of formula 3) Chloroacetyl chloride (300g, 2.65mol) was charged slowly at 10-20° C to a stirred mixture containing imidazole (630g, 9.29mol), benzyl alcohol (300ml, 2.92mol) and acetonitrile (900ml). Temperature was raised to 50-55° C and stirred for 12 hours. Acetonitrile was distilled out under vacuum at 55-60° C and finally degassed for lhour at 55-60° C. Water was added to the residue and the product extracted into ethyl acetate. The ethyl acetate extract was washed successively with 10% sodium bicarbonate solution and water and then concentrated and degassed to get 467g of crude benzyl 1-imidazolylacetate compound of formula 3.
  • a suspension of imidazol-1 -ylacetic acid, compound of formula 2 (50g, 0.396mol) and phosphorous acid (48.7g, 0.594mol) in sulfolane (180ml) was heated to 75° C for 30 min.
  • the mixture was cooled to 35-40° C and phosphorous trichloride (117ml, 1.346mol) was gradually introduced while maintaining the temperature between 35-45° C.
  • the mixture was heated to 63-67° C for 3 hours, whereby white solid results. It was then cooled to 0- 5° C and quenched by slow addition of water (500ml) at 0-5° C over a period of 1 hour.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a process for preparation of 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid, compound of formula (1), said process comprising (a) reacting imidazole with chloroacetyl chloride and benzyl alcohol in homogenous system in one pot to obtain benzyl 1-imidazolylacetate, compound of formula (3); (b) debenzylating benzyl 1-imidazolylacetate, a compound of formula (3) to imidazole 1-ylacetic acid, compound of formula (2) and (c) converting compound of formula (2) to compound of formula (1).

Description

A PROCESS FOR THE PREPARATION OF 2-(IMIDAZOL-l-YL)-l- HYDROXYETHANE-l.l-DIPHOSPHONIC ACID
The present invention relates to a process for the preparation of 2~(imidazol-l-yl)-l- hydroxyethane- 1 , 1 -diphosphonic acid, compound of formula 1, commonly known as zoledronic acid (INN Name) used as medicament for treatment of diseases associated with impairment of calcium metabolism.
Figure imgf000003_0001
Formula 1
BACKGROUND OF THE INVENTION
United States Patent No. 4,939,130 (Assigned to: Ciba-Geigy Corporation) discloses the preparation of zoledronic acid, compound of formula 1, from imidazol-1-ylacetic acid, compound of formula 2, o Formula 2 by two methods viz.
(a) Compound of formula 2 or its acid chloride is treated with suitable triphosphite of formula P(OR)3 to give an intermediate compound which is reacted with a diphosphite of formula HPO(OR)2 to give the diphosphonate, which on hydrolysis gives zoledronic acid, compound of formula 1.
(b) Compound of formula 2 is treated with phosphorous acid and phosphorus trihalide in halogenated hydrocarbons followed by hydrolysis to give zoledronic acid, compound of fomiula 1. This patented process however does not disclose the process for preparing imidazol-1 - ylacetic acid, compound of formula 2, the starting raw material for synthesis of zoledronic acid. Birkofer et.al in Chemische Berichte 1960, 93, 2804-9 reports the synthesis of imidazol- 1 -ylacetic acid by hydrolysis of trimethylsilyl 1-imidazoleacetate. This process uses silylating agents which are expensive.
Prior art methods (a) Zaderenko et.al in J. Org. Chem. 1994, 59, 6268-73 and (b) PCT publication 9955670 prepare different alkyl or alkylaryl esters of imidazol-1 -ylacetic acid. Further method (b) describes hydrolysis of the ester of imidazol-1 -ylacetic acid to imidazol-1 -ylacetic acid, compound of formula 2, by heating in water. The preparation of the ester involves treating imidazole with the required haloacetates in presence of potassium hydroxide and potassium carbonate in methylene dichloride and facilitator like l,5-bis[(N-benzyl-N,N-diethylammonio)ethyl]ether dichloride (BBDED). The method reported in prior art for synthesis of esters has several disadvantages, (i) It requires usage of haloacetates, which are relatively expensive, (ii) Additional base is used in the reaction which is inorganic that makes the reaction mixture heterogeneous and requires use of facilitator to facilitate the reaction, (iii) The yields of most of the esters obtained by this method are low. Method (a) prepares benzyl esters of imidazol-1 -yl acetic acid in low yield. Method (b) discloses preparation of methyl and malonyl esters of imidazol-1 - ylacetic acid in 70-80% and 49% yield respectively. Hydrolysis of these compounds will further reduce the overall yield of imidazol-1 -ylacetic acid, compound of fomiula 2. The process of the present invention prepares the benzyl ester of imidazol-1 -ylacetic acid, compound of fomiula 3, in greater than 80% yield. All the above mentioned prior art references prepare the haloacetate or trimethylsilyl haloacetate separately and then treat it with imidazole. The process of the present invention prepares the compound of formula 3, by directly reacting imidazole with benzyl alcohol and chloroacetyl chloride in one pot. It does not need a separate unit operation for preparation of the haloacetatae.
Surprisingly the benzyl ester of imidazol-1 -ylacetic acid, compound of formula 3, may be prepared in high yields, in one pot in a homogenous system by a novel method without the use of expensive haloacetates. The benzyl 1-imidazolylacetate, compound of fomiula 3, is then converted to imidazol-1 -ylacetic acid, compound of fomiula 2, by catalytic hydrogenolysis or by acid hydrolysis which is further converted to compound of fomiula 1.
Figure imgf000005_0001
Fomiula 3 Formula 2
OBJECTS OF THE INVENTION:
The object of the present invention is to provide a simple and cost-effective process for the preparation of compound of fomiula 1.
Another object of the present invention is to prepare compound of fomiula 3 by a novel process in high yields by simple, convenient and commercially viable method from readily available and cheap reagents.
The compound of fomiula 3 can be used as an intermediate for the preparation of imidazole derivatives such as compound of fomiula 1.
SUMMARY OF INVENTION : The present invention provides a process for preparation of 2-(imidazol-l-yl)- 1- hydroxyethane- 1,1 -diphosphonic acid, compound of formula 1, said process comprising
Figure imgf000006_0001
Formula 1
(a) reacting imidazole with chloroacetyl chloride and benzyl alcohol in a homogenous system in one pot to obtain benzyl 1- imidazolylacetate, compound of formula 3;
Figure imgf000006_0002
Formula 3 (b) debenzylating benzyl 1-imidazolylacetate, compound of formula 3, to imidazol-1 - ylacetic acid, compound of formula 2, and
Figure imgf000006_0003
Formula 2 (c) converting compound of fomiula 2 to compound of fomiula 1.
The present invention also provides a process for preparing benzyl 1-imidazolylacetate, compound of formula 3, said process comprising
Figure imgf000006_0004
Formula 3 reacting imidazole with chloroacetyl chloride and benzyl alcohol in a homogenous system in one pot.
DETAILED DESCRIPTION OF THE INVENTION We have now developed a high yielding commercially viable process for the preparation of 2-(imidazol-l-yl)-l-hydroxyethane- 1,1 -diphosphonic acid, compound of fomiula 1. According to the process of the present invention 2-(imidazol-l-yl)-l-hydroxyethane-l,l- diphosphonic acid, compound of fomiula 1, may be prepared from compound of foπnula 3
Figure imgf000007_0001
Foπnula 1
Figure imgf000007_0002
Figure imgf000007_0003
Fomiula 2
This process prepares compound of formula 3 from cheap and readily available raw materials in a single pot. The compound of fomiula 3 is then debenzylated to compound of formula 2 which is then converted to compound of foπnula 1.
According to one embodiment of the process of the present invention the compound of foπnula 3, benzyl 1-imidazolylacetate, is prepared by reaction of imidazole with chloroacetyl chloride and benzyl alcohol in an organic solvent.
The process of the present invention prepares compound of fomiula 3, benzyl- 1- imidazolyl acetate, in one pot starting from chloroacetyl chloride, benzyl alcohol and imidazole. Imidazole is present in molar excess over chloroacetyl chloride and acts as reactant as well as base. The molar ratio of chloroacetyl chloride: imidazole may be selected in the range from 1 :2 to about 1 :6, preferably 1 :3.
Accordingly the process of the present invention is carried out in absence of additional base. The use of excess of imidazole avoids use of an additional inorganic base such as hydroxides, carbonates of alkali and alkaline earth metal salts such as potassium hydroxide &/or potassium carbonate and the like, or an organic base like tertiary alkylamines, such as triethylamine, diisopropylethylamine etc.
The reaction mixture of the present invention is homogenous, as imidazole is soluble in organic solvent, and a separate additional base is not used in the reaction. Accordingly the process of the present invention obviates the requirement of a facilitator such as a phase transfer catalyst.
The organic solvent may be selected from non-polar solvents like linear or cyclic aliphatic or aromatic hydrocarbons such as n-hexane, n-heptane, cyclohexane, methylcyclohexane, toluene, ethylbenzene, xylene and the like; aliphatic or aromatic halogenated hydrocarbons such as methylene dichloride, ethylene dichloride, tetrachloroethane, trichloroethane, chlorobenzene, dichlorobenzene and the like; ethereal solvents, such as diethylether, di-isopropylether, dioxane, tetrahydrofuran and the like; esters such as ethyl acetate, tert-butyl acetate and the like; or inert polar aprotic solvents such as acetonitrile, sulfolane and the like.
The reaction may be carried out at temperature ranging from 30 to 100°C, preferably 40 to 70°C. The compound of formula 3 is thus prepared in high yields by simple, convenient and commercially viable method from readily available, and cheap reagents with reduced number of unit operations.
According to another embodiment of the process of the present invention the compound of fomiula 2, imidazol-1 -ylacetic acid, is obtained by debenzylating benzyl 1- imidazolyl acetate, compound of formula 3. The debenzylation may be carried by catalytic hydrogenolysis or by acidic hydrolysis.
Accordingly the debenzylation by catalytic hydrogenolysis may be performed in presence of metal catalysts like palladium, platinum, ruthenium or rhodium and the like. For instance the catalytic hydrogenolysis may be carried out in a solvent at atmospheric pressure or at higher pressures, at temperature between 5 and 100°C. The solvent maybe selected from a polar protic solvent such as methanol, ethanol, isopropanol, acetic acid and the like; or in aromatic hydrocarbons such as toluene, or esters such as ethyl acetate, tert-butyl acetate and the like
Alternatively, debenzylation may be perfoπned by acidic hydrolysis with a mineral or organic acid, wherein mineral acid may be selected from hydrochloric, sulfuric, hydrobromic and the like; and the organic acid may be selected from acetic, oxalic, para- toluenesulfonic, methaesulfonic and the like.
Acidic hydrolysis may be earned out by at temperature of about 20 -100 °C for 2-6 hours preferably at about 40 to 70°C.
The compound of fomiula 2, imidazol-1 -ylacetic acid is then converted to 2-(imidazol-l- yl)-l-hydroxyethane- 1,1 -diphosphonic acid, compound of fomiula 1 using standard methods known to those skilled in the art such as United States Patent No. 4,939,130. Preferably a process disclosed in our copending Indian Patent Application No. 837/MUM/2003 may be used.
The invention is illustrated but not restricted by the description in the following examples Examples
Example 1 Synthesis of benzyl 1-imidazolyl acetate (compound of formula 3) Chloroacetyl chloride (300g, 2.65mol) was charged slowly at 10-20° C to a stirred mixture containing imidazole (630g, 9.29mol), benzyl alcohol (300ml, 2.92mol) and acetonitrile (900ml). Temperature was raised to 50-55° C and stirred for 12 hours. Acetonitrile was distilled out under vacuum at 55-60° C and finally degassed for lhour at 55-60° C. Water was added to the residue and the product extracted into ethyl acetate. The ethyl acetate extract was washed successively with 10% sodium bicarbonate solution and water and then concentrated and degassed to get 467g of crude benzyl 1-imidazolylacetate compound of formula 3.
Example 2
Preparation of imidazol-1 -ylacetic acid (compound of fomiula 2)
A solution of the crude benzyl 1-imidazolyl acetate, compound of formula 3 (450g, 2. OS mol) as obtained in example 1, in 2-propanol (2.251tr) was hydrogenated in an autoclave with 50% wet 5.0% w/w palladium-carbon (22.5g) at 2.0kg pressure at ambient temperature for 2 hours. The reaction mixture was filtered and the cake containing product and palladium charcoal was washed with 2-propanol. The cake was then stiπed for 30 minutes with water and filtered. The aqueous filtrate was concentrated and degassed by co-distillation with 2-propanol. The residue obtained was suspended and stirred in methanol (300ml), filtered and dried to obtain imidazol-1 -ylacetic acid, compound of fomiula 2, 185g (purity > 99.0%). Example 3
Preparation of imidazol-1 -ylacetic acid (compound of fomiula 2)
A solution of the crude benzyl- 1-imidazolyl acetate, compound of fomiula 3 (25g) as obtained in example 1, in 10%o HCl (50ml) was heated to 65° C for 4 hours. The reaction mixture was washed with toluene (50ml). The aqueous layer was concentrated and degassed by co-distillation with toluene. The residue obtained was suspended in acetone, stured, filtered and dried to obtain imidazol-1 -ylacetic acid, compound of formula 2.
Example 4
Preparation of zoledronic acid (compound of fonriula 1)
A suspension of imidazol-1 -ylacetic acid, compound of formula 2 (50g, 0.396mol) and phosphorous acid (48.7g, 0.594mol) in sulfolane (180ml) was heated to 75° C for 30 min. The mixture was cooled to 35-40° C and phosphorous trichloride (117ml, 1.346mol) was gradually introduced while maintaining the temperature between 35-45° C. The mixture was heated to 63-67° C for 3 hours, whereby white solid results. It was then cooled to 0- 5° C and quenched by slow addition of water (500ml) at 0-5° C over a period of 1 hour. The resulting clear solution was heated at 100° C for 3 hours, cooled to ambient temperature and charcoalized. Acetone was added to the charcoalized solution. The mixture was then stirred for 4 hours at 20-25° C and the crystallized product was filtered, washed sequentially with chilled water, acetone and dried to obtain zoledronic acid.

Claims

WE CLAIM:
1. A process for preparing 2-(imidazol-l-yl)-l-hydroxyethane- 1,1 -diphosphonic acid, compound of fomiula 1, said process comprising
Figure imgf000013_0001
Foπnula 1
(a) reacting imidazole with chloroacetyl chloride and benzyl alcohol in a homogenous system in one pot to obtain benzyl 1-imidazolylacetate, compound of fomiula 3;
Formula 3
(b) debenzylating the benzyl 1-imidazolylacetate, compound of foπnula 3, to imidazol-1 -ylacetic acid, compound of foπnula 2; and
Figure imgf000013_0003
Fomiula 2 (c) converting compound of formula 2 to compound of formula 1.
2. A process as claimed in claim 1 step (a) wherein molar proportion of chloroacetyl chloride: imidazole is in the range of about 1 :2 to 1 :6.
3. A process as claimed in claim 1 step (a) wherein the reaction is carried out in absence of additional base.
4. A process as claimed in claim 1 step (a) wherein the reaction is carried out in absence of facilitator.
5. A process as claimed in claiml step (b) wherein debenzylation is carried out by catalytic hydrogenation or acidic hydrolysis.
6. A process for preparing benzyl 1-imidazolylacetate, compound of formula 3, said process comprising
Figure imgf000014_0001
Foπnula 3 reacting imidazole with chloroacetyl chloride and benzyl alcohol in a homogenous system in one pot.
7. A process as claimed in claim 6 wherein molar proportion of chloroacetyl chloride: imidazole is in the range of about 1 :2 to 1 : 6. process for the preparation of compound of formula 1 as claimed in claims 1 to substantially as herein described and illustrated by examples 1 to 4.
PCT/IN2004/000320 2003-10-17 2004-10-18 A process for the preparation of 2-(imidazol-1-yl)-1-hydroxyethane-1, 1-diphosphonic acid Ceased WO2005066188A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1094/MUM/2003 2003-10-17
IN1094MU2003 2003-10-17

Publications (1)

Publication Number Publication Date
WO2005066188A1 true WO2005066188A1 (en) 2005-07-21

Family

ID=34746666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000320 Ceased WO2005066188A1 (en) 2003-10-17 2004-10-18 A process for the preparation of 2-(imidazol-1-yl)-1-hydroxyethane-1, 1-diphosphonic acid

Country Status (1)

Country Link
WO (1) WO2005066188A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109542A3 (en) * 2006-03-21 2007-11-01 Albemarle Corp Process for manufacturing bisphosphonic acids
WO2007125521A3 (en) * 2006-05-02 2008-01-10 Ranbaxy Lab Ltd Polymorphic form of zoledronic acid and processes for their preparation
WO2008056129A1 (en) * 2006-11-06 2008-05-15 Hovione Inter Limited Process for the preparation of biphosphonic acids and salts thereof
WO2010050830A1 (en) * 2008-10-31 2010-05-06 Zakłady Farmaceutyczne Polpharma Sa Process for the preparation of [1-hydroxy-2-(1h-imidazol-1-yl)- ethylidene]bisphosphonic acid
US20100197931A1 (en) * 2005-07-28 2010-08-05 Gador S.A. Crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] ZHU J. ET AL: "Synthesis of zoledronic acid", accession no. STN Database accession no. 2003-159671 *
DATABASE CAPLUS LI J. ET AL: "Improved process for the synthesis of zoledronic acid as a new drug for treating hypercalcemia" *
ZHONGGUO XINYAO ZAZHI, vol. 12, no. 1, 2003, pages 39 - 40 *
ZHONGGUO YAOWU HUAXUE ZAZHI, vol. 12, no. 3, 2002, pages 164 - 165 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20100197931A1 (en) * 2005-07-28 2010-08-05 Gador S.A. Crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it
US8952172B2 (en) * 2005-07-28 2015-02-10 Gador S.A. Crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it
WO2007109542A3 (en) * 2006-03-21 2007-11-01 Albemarle Corp Process for manufacturing bisphosphonic acids
WO2007125521A3 (en) * 2006-05-02 2008-01-10 Ranbaxy Lab Ltd Polymorphic form of zoledronic acid and processes for their preparation
WO2008056129A1 (en) * 2006-11-06 2008-05-15 Hovione Inter Limited Process for the preparation of biphosphonic acids and salts thereof
RU2425049C2 (en) * 2006-11-06 2011-07-27 Ховионе Интер Лимитед Method of producing biphosphonic acids and their salts
WO2010050830A1 (en) * 2008-10-31 2010-05-06 Zakłady Farmaceutyczne Polpharma Sa Process for the preparation of [1-hydroxy-2-(1h-imidazol-1-yl)- ethylidene]bisphosphonic acid
US8524912B2 (en) 2008-10-31 2013-09-03 Zaklady Farmaceutyczne Polpharma Sa Process for the preparation of [1-hydroxy-2-(1H-imidazol-1-yl)- ethylidene]bisphosphonic acid
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Similar Documents

Publication Publication Date Title
US7560575B2 (en) Process for preparation of racemic Nebivolol
CS244408B2 (en) Method of n-phosphonomethylglycine production
US5453537A (en) Method for preparing an N-phosphonomethylglycine
WO2005066188A1 (en) A process for the preparation of 2-(imidazol-1-yl)-1-hydroxyethane-1, 1-diphosphonic acid
US20090048457A1 (en) Process for preparation of racemic nebivolol
US6444826B1 (en) Processes and intermediates for preparing substituted chromanol derivatives
NO861053L (en) NEW PHOSPHORUS COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND USE FOR THE MANUFACTURE OF HERBICIDES.
CN102186835B (en) Process for preparing nebivolol
GB1562836A (en) Preparing l-(cis)-1,2-epoxypropyl phosphonic acid
WO2012098563A2 (en) One-pot preparation of cyclobenzaprine hydrochloride
CA3093047A1 (en) Improved process for preparation of intermediates
CA2418970C (en) Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts
US7745649B2 (en) Processes for preparing tetrahydropyran-4-one and pyran-4-one
EP0738720B1 (en) Process for producing 1-(2-chlorphenyl)-5(4H)-tetrazolinone
KR20090130117A (en) Multistage Synthesis of Ibandronate
EP0404175B1 (en) Process for preparing imidazole derivatives
EP2038291A2 (en) Process for the synthesis of ibandronate sodium
Yamato et al. A new method for the preparation of 2-alkoxybenzoxazoles
EP0260102B1 (en) Chemical process
RU2179169C2 (en) Method of synthesis of 2-trifluoromethyl-10-[3-(1-methyl-piperazinyl-4)-propyl]- phenothiazine dihydrochloride
JPH04112845A (en) Production method of hydroxystilbenes
KR100408431B1 (en) Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one or pharmaceutically acceptable salts thereof
JP4671091B2 (en) Process for producing 1-substituted-2-methylpiperazine
US6603003B2 (en) Method for the preparation of piperazine and its derivatives
KR101426641B1 (en) Method for manufacturing novel intermediate compound useful for the preparation of urocanic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase